Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Sun Pharma Advanced Research company Limited has developed a dry powder inhaler of compound
SPARC1316 for oral inhalation. This clinical study is a Phase I/IIa study to investigate the
safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending
doses of S0597 administered by oral inhalation to healthy volunteers and asthma patients.